Charles River Laboratories (CRL) Tops Q2 EPS by 5c, beats revenue, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $344.87 +9.33%
EPS Growth %: +22.2%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
FNLC, LSBK, OVLY, More
EPS Growth %: +22.2%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.69, $0.05 better than the analyst estimate of $2.64. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $10.30-$10.90.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Hexcel falls on revenue miss and weak guidance
- Lake Shore Bancorp (LSBK) Tops Q3 EPS by 31c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
